Strategic Blueprint LLC Acquires 1,039 Shares of Stryker Corporation $SYK

Strategic Blueprint LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 79.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 2,350 shares of the medical technology company’s stock after buying an additional 1,039 shares during the period. Strategic Blueprint LLC’s holdings in Stryker were worth $930,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC raised its position in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Stryker by 16.4% in the 1st quarter. GAMMA Investing LLC now owns 5,574 shares of the medical technology company’s stock worth $2,075,000 after purchasing an additional 785 shares during the last quarter. Spire Wealth Management raised its position in shares of Stryker by 1.2% in the 1st quarter. Spire Wealth Management now owns 3,473 shares of the medical technology company’s stock worth $1,293,000 after purchasing an additional 42 shares during the last quarter. Golden State Wealth Management LLC raised its position in shares of Stryker by 298.5% in the 1st quarter. Golden State Wealth Management LLC now owns 793 shares of the medical technology company’s stock worth $295,000 after purchasing an additional 594 shares during the last quarter. Finally, HBK Sorce Advisory LLC raised its position in shares of Stryker by 5.0% in the 1st quarter. HBK Sorce Advisory LLC now owns 847 shares of the medical technology company’s stock worth $315,000 after purchasing an additional 40 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on SYK. BTIG Research lifted their price target on Stryker from $407.00 to $408.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Truist Financial lowered their price target on Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research report on Wednesday, October 15th. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research report on Friday. Finally, Rothschild & Co Redburn began coverage on Stryker in a research report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $432.24.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $381.86 on Friday. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The business has a 50-day simple moving average of $379.84 and a two-hundred day simple moving average of $379.73. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $145.99 billion, a price-to-earnings ratio of 50.58, a price-to-earnings-growth ratio of 2.76 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is currently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.